Stocks

BioNTech (NASDAQ:BNTX) Stock Price Up 1.3% - Is Now the Time to Invest?

Published December 13, 2024

BioNTech SE (NASDAQ:BNTX) experienced a rise of 1.3% in its share price during trading on Thursday. The stock reached a high of $121.24 before settling at $120.84. Throughout the day, 80,496 shares were exchanged, which is a significant decrease of 90% from the average volume of 806,855 shares in a typical session. The stock's previous closing price was $119.34.

Analyst Ratings Changes

4 Reasons Pfizer Could Be a Value Play You Can't Miss

BioNTech's share performance has captured the attention of several analysts. Notably, Bank of America raised its price target on the company from $125.00 to $150.00, assigning a "buy" rating in a report dated September 16th. On September 18th, Wells Fargo initiated coverage, offering an "overweight" rating with a target price set at $170.00. Additionally, UBS Group adjusted their price target from $97.00 to $131.00 and gave the stock a "neutral" rating in a report that same day. Jefferies Financial Group made a significant upgrade, moving from a "hold" rating to a "buy" and increasing their price target from $96.00 to $150.00 on September 17th. Furthermore, on November 19th, Evercore ISI changed its rating from "in-line" to "outperform," raising the price target from $110.00 to $125.00. In total, four analysts have rated the stock as a hold, while twelve recommended a buy, and one gave a strong buy rating. As per MarketBeat's data, BioNTech currently holds a consensus rating of "Moderate Buy" with an average price target of $140.76.

View Our Latest Stock Analysis on BNTX

BioNTech Price Performance

Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?

In terms of technical performance, BioNTech's 50-day moving average is recorded at $113.89, while its 200-day moving average stands at $100.03. The company boasts a market capitalization of $28.92 billion. Its price-to-earnings ratio is calculated at -57.54, along with a beta value of 0.22. Furthermore, BioNTech shows a debt-to-equity ratio of 0.01, a current ratio of 7.33, and a quick ratio of 7.21.

The latest quarterly earnings report from BioNTech was released on November 4th. The company reported an earnings per share (EPS) of $0.81, surpassing analysts' expectations of a loss of $1.26 by a significant margin of $2.07. BioNTech posted a negative return on equity of 2.35% and recorded a negative net margin of 15.16%. During the same quarter, the company generated revenue of $1.24 billion, which exceeded the consensus estimate of $514.08 million. This represents a 38.9% increase in revenue compared to the previous year’s same quarter, where it reported an EPS of $0.73. Analysts predict that BioNTech SE will have an EPS of -3.72 for the current year.

Institutional Trading of BioNTech

Novavax Plunges on Earnings Miss: Falling Knife or Buying Opportunity?

Recently, several institutional investors have adjusted their positions in BioNTech. GAMMA Investing LLC increased its holdings by 21.7% during the third quarter, now owning 623 shares valued at $74,000 after acquiring an additional 111 shares. Blue Trust Inc. saw a substantial increase of 491.1% in their shares during the same period, bringing their total to 467 shares valued at $55,000 after purchasing 388 additional shares. Also, Gallacher Capital Management LLC raised its stake by 12.1%, now owning 3,657 shares worth $294,000. TD Asset Management Inc. enhanced its holdings by 6.1%, possessing 7,590 shares worth about $612,000 following an additional purchase of 435 shares. Lastly, Planning Capital Management Corp made a remarkable increase of 45,000.0%, now holding 451 shares valued at $54,000 after buying 450 more shares. Currently, 15.52% of BioNTech's stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE is a biotechnology company focused on developing and commercializing innovative immunotherapies for cancer and infectious diseases. The company is working on several product candidates within its FixVac platform, which includes BNT111 in phase II trials for advanced melanoma, BNT112 in phase I/IIa trials for prostate cancer, BNT113 for treating HPV 16-positive head and neck cancers in phase II, BNT114 targeting triple-negative breast cancer, BNT115 in phase I for ovarian cancer, and BNT116 in phase I for non-small cell lung cancer.

Should you invest $1,000 in BioNTech right now?

Before making a decision on BioNTech, it is important to gather information from reliable sources.

MarketBeat tracks top-rated analysts and their stock recommendations. They have identified five stocks that analysts favor for investment right now, which do not include BioNTech.

While BioNTech has a "Moderate Buy" rating from analysts, it may be beneficial to consider other recommendations from leading experts.

Explore analyst suggestions for better investment opportunities.

BioNTech, Stocks, Investment